ArticleFrontiers in pharmacology2025
Intraoperative dexmedetomidine use associated with prolonged postanesthesia care unit recovery time after lung resection: a retrospective cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of preoperative intranasal dexmedetomidine in adults: a systematic review and meta-analysis of randomized controlled trials.Brazilian journal of anesthesiology (Elsevier)Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexmedetomidine, despite its wide-ranging benefits, may also pose a risk of delayed recovery in the postanesthesia care unit (PACU). Few studies have examined the relationship between dexmedetomidine and delayed recovery in the PACU after lung resection. Therefore, this retrospective cohort study aimed to investigate the effect of dexmedetomidine on PACU recovery time. Methods: This study identified 1,397 eligible patients [dexmedetomidine-free (NO-DEX) group, n = 638; intraoperative dexmedetomidine use (DEX) group, n = 759] among 1,980 patients undergoing lung resection from January 2020 to December 2023. The primary outcome was the relationship between dexmedetomidine exposure and the risk of prolonged PACU recovery time; secondary outcomes were independent risk factors affecting PACU recovery time. The data were analyzed using propensity score matching and univariate and multivariate logistic regression analyses, as appropriate. In addition, we also developed a nomogram, which was evaluated using the calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). Results: After propensity score matching, there were 521 patients in each group. The incidence of PACU recovery time exceeding 60 min was 25.48%. Univariate logistic regression analysis showed that intraoperative dexmedetomidine use was associated with the risk of prolonged PACU recovery time [odds ratio (OR): 1.58; 95% confidence interval (CI): 1.18-2.11; Conclusion: Our data demonstrated that intraoperative dexmedetomidine use was associated with prolonged PACU recovery time following lung resection, potentially increasing the pressure on busy recovery rooms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.